NOVARTIS FINANCE CORPORATION – Trademark Portfolio
Entity Type: 03
NOVARTIS FINANCE CORPORATION holds 17 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 15 filings in this category. The portfolio also extends into Class 31 (Natural Agricultural Products) across 2 Nice Classification classes. Currently, 5 trademarks are registered. Notable registered marks include ALAMO, VANGARD, APRON XL, EYESCRUB, and CALIBER 90. The owner is based in SUMMIT, NJ.
564 MORRIS AVENUE
SUMMIT, NJ 07901
Showing of trademarks Trademarks
Trademark Classifications
NOVARTIS FINANCE CORPORATION's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Raw and unprocessed agricultural, aquacultural, horticultural and forestry products
Frequently Asked Questions
How many trademarks does NOVARTIS FINANCE CORPORATION have?
NOVARTIS FINANCE CORPORATION has 17 U.S. trademarks filed with the USPTO. Of these, 5 registered, 12 cancelled.
What trademark classes does NOVARTIS FINANCE CORPORATION file in?
NOVARTIS FINANCE CORPORATION files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 31 (Natural Agricultural Products). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are NOVARTIS FINANCE CORPORATION's most well-known trademarks?
NOVARTIS FINANCE CORPORATION's registered trademark portfolio includes well-known marks such as ALAMO, VANGARD, APRON XL, EYESCRUB, and CALIBER 90. These are among 5 currently registered trademarks in the portfolio.
What is NOVARTIS FINANCE CORPORATION's trademark registration success rate?
NOVARTIS FINANCE CORPORATION has a 29% trademark registration rate, with 5 out of 17 resolved applications resulting in successful registration. Currently, 0 applications are pending review.